source
- Arrowhead Pharma to pay $215 million for PRV in its latest acquisitionArrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year. The purchase aligns with Arrowhead's strategy of…
- Expedition Therapeutics raises $115M Series B for China-sourced COPD candidateExpedition Therapeutics, a US biotech, announced a $115 million Series B financing round. The capital will be used to advance its COPD drug candidate that is being developed from a China-sourced p…